关键词:

上皮性卵巢癌, IGSF9, 预后, 临床病理特征, 肿瘤转移

Abstract:

Objective　To study the expression of immunoglobulin superfamily member 9 (IGSF9) in epithelial ovarian cancer (EOC), to analyze its relationship with prognosis and clinicopathological characteristics of EOC patients, and to explore the effect of IGSF9 on the metastatic ability of ovarian cancer cells. Methods　The expression of IGSF9 mRNA was analyzed by dynamic analysis website of gene expression profile data (GEPIA). The relationship between IGSF9 expression and the patients' survival time was analyzed by the Kaplan-Meier Plotter database. A total of 76 paraffin samples from the primary lesions of the EOC patients who were treated in Department of Gynecology, Tengzhou Central People's Hospital from June 2010 to June 2020 and 30 paraffin samples from the normal ovarian tissue removed due to other diseases during the same period were selected. The expressions of IGSF9 in the EOC patients' tissue and normal tissue were detected by the immunohistochemical staining; the correlation between IGSF9 expression and clinicopathological characteristics was analyzed. The SKOV3 ovarian cancer cell line interfered by IGSF9 was constructed by shRNA. Real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) was used to identify the interference effect. The Transwell chamber method was used to detect the metastasis ability of SKOV3 cell line after IGSF9 interference. t test, analysis of variance, and χ² test were applied. Results　The GEPIA database showed that the expression level of IGSF9 in EOC was 21.8 times that in normal tissue. The 5-year overall survival and progression-free survival of the patients with high IGSF9 expression were poor. The high expression rates of IGSF9 in the EOC tissue and normal ovarian tissue were 69.7% and 16.7%, respectively. The expression of IGSF9 protein was correlated with FIGO stage, peritoneal metastasis, and serum carbohydrate antigen (CA-125) level in the EOC patients. Interference with IGSF9 expression resulted in decreased metastatic ability of ovarian cancer cells. Conclusions　The increased expression of IGSF9 in EOC is related to poor prognosis and poor clinicopathological characteristics of EOC patients. IGSF9 can promote the metastasis of ovarian cancer cells. IGSF9 may promote the progress of EOC, and has certain value for the diagnosis, treatment, and prognosis evaluation of EOC patients.

Key words:

Epithelial ovarian cancer, IGSF9, Prognosis, Clinicopathological features, Tumor metastasis